ACRX News Acelrx Pharmaceuticals 8.96 $ACRX Cat

ACRX News Acelrx Pharmaceuticals 8.96 $ACRX

Catamaran EPS Tops, But Stock Falls On Weak Guidance
at Investor's Business Daily - Thu Feb 26, 10:59AM CST
Catamaran (CTRX) surpassed fourth-quarter earnings and sales estimates on Thursday, but shares sank on its weak full-year EPS outlook. The provider of pharmacy benefit management services saw adjusted earnings climb 19.6% to 67 cents a share in Q4,...
ESRX: 84.54 (-0.55), CTRX: 51.38 (-1.40), BRLI: 35.24 (+0.19), AAC: 36.61 (-0.72), CVS: 104.17 (+0.73), RAD: 8.17 (+0.02)

AAC Holdings (AAC) Looks Good: Stock Gains 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 8:25AM CST
AAC Holdings (AAC) was a big mover last session, with shares rising over 12% on the day.
CHE: 116.49 (+1.27), AAC: 36.61 (-0.72)

AAC Holdings beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:31PM CST

AAC: 36.61 (-0.72)

AAC Holdings, Inc. Expands De Novo Pipeline with Hospital Entry in Southern California
Business Wire - Tue Feb 03, 5:45AM CST
AAC Holdings, Inc. (NYSE: AAC), added to its pipeline of de novo growth opportunities with the entry into a definitive agreement for the acquisition, through its subsidiary, Behavioral Healthcare Realty, LLC, of an 84-licensed-bed hospital in Aliso Viejo, California for an aggregate of $13.5 million in cash. The closing is expected to occur during the first quarter of 2015 and is subject to certain closing conditions, including the amendment or removal of certain use restrictions on the property.
AAC: 36.61 (-0.72)

AAC Holdings, Inc. Schedules Fourth Quarter 2014 Earnings Release and Conference Call Dates
Business Wire - Mon Jan 26, 3:19PM CST
AAC Holdings, Inc. (NYSE: AAC) announced details for the release of its results for the fourth quarter and year ended December 31, 2014.
AAC: 36.61 (-0.72)

AAC Holdings, Inc. Takes Next Step to Expand Outpatient Treatment Strategy with Execution of Definitive Acquisition Agreement in Rhode Island
Business Wire - Mon Jan 26, 5:45AM CST
AAC Holdings, Inc. (NYSE: AAC), through its subsidiary AAC Rhode Island Acquisition Sub, LLC, has signed a definitive agreement to acquire Clinical Services of Rhode Island, Inc. ("CSRI" , a provider of intensive outpatient substance abuse treatment services, for $665,000 in cash and $1,335,000 worth of restricted shares of AAC Holdings' common stock. The acquisition, which is subject to certain closing conditions such as the assignment of certain contracts and the receipt of certain licenses necessary to operate the business, is expected to close during the second quarter of 2015.
AAC: 36.61 (-0.72)

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BOFI: 90.25 (+0.29), BGMD: 0.74 (+0.04), AUO: 5.26 (-0.08), AAC: 36.61 (-0.72), AAPL: 130.41 (+1.62)

AAC Holdings, Inc. Provides Facility Updates in California, Florida and Nevada
Business Wire - Tue Jan 20, 5:45AM CST
AAC Holdings, Inc. (NYSE: AAC), disclosed that on January 8, 2015, its new substance abuse outpatient center in Las Vegas, Nevada, received full licensure for intensive outpatient treatment services and has begun treating patients at the facility.
AAC: 36.61 (-0.72)

AAC Holdings, Inc. Plans for Growth with Lease Signing for New Headquarters
Business Wire - Mon Jan 12, 2:16PM CST
AAC Holdings, Inc. (NYSE: AAC), announced plans to support its next stage of growth with the signing by its wholly owned subsidiary American Addiction Centers, Inc. of a 102,000-square-foot, 10-year lease at 200 Powell Place in Brentwood, Tennessee for its new corporate headquarters and call center. The Company expects to begin transitioning from its current space in the third quarter of 2015 with a completed move anticipated by late third quarter 2015.
AAC: 36.61 (-0.72)

Quest Diagnostics Hits 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 12:40PM CST
Last month, Quest Diagnostics' (DGX) Simplexa Flu A/B & RSV Direct Kit won U.S. Food & Drug Administration (FDA) clearance for testing eight additional influenza viruses.
PMC: 24.37 (+0.12), AFAM: 33.20 (+2.05), AAC: 36.61 (-0.72), DGX: 71.10 (-0.19)

AAC Holdings, Inc. Executes Growth Strategy with Agreement to Acquire In-Network Substance Abuse Treatment Provider in Florida for $13 Million
Business Wire - Mon Dec 15, 3:01PM CST
American Addiction Centers, Inc., a subsidiary of AAC Holdings, Inc. (NYSE: AAC), has signed a definitive agreement to acquire Recovery First, Inc., a Florida-based provider of substance abuse treatment and rehabilitation services, for $13 million in cash. The acquisition, which is subject to certain closing conditions such as the assignment of certain contracts and the receipt of certain licenses necessary to operate the business, is expected to close during the first quarter of 2015.
AAC: 36.61 (-0.72)

Is AAC Holdings (AAC) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:42AM CST
One stock that might be an intriguing choice for investors right now is AAC Holdings as this security in the Specialized Health Services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AAC: 36.61 (-0.72)

Surging Earnings Estimates Signal Good News for AAC Holdings (AAC) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:31AM CST
AAC Holdings (AAC) sees solid earnings estimate revisions, and the stock is showing decent short-term momentum as well, rising nearly 45% in the past month.
AAC: 36.61 (-0.72)

AAC Holdings EPS of $0.14
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:55PM CST

AAC: 36.61 (-0.72)

AAC Holdings, Inc. Reports Third Quarter 2014 Results
Business Wire - Wed Nov 05, 4:18PM CST
AAC Holdings, Inc. (NYSE: AAC), the parent holding company of American Addiction Centers, Inc., announced its results for the third quarter ended September 30, 2014. All comparisons included in this release are for the third quarter of 2014 to the third quarter of 2013 unless otherwise noted.
AAC: 36.61 (-0.72)

AAC Holdings, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call Dates
Business Wire - Tue Oct 28, 9:21AM CDT
AAC Holdings, Inc. (NYSE: AAC), the parent holding company of American Addiction Centers, Inc., announced details for the release of its results for the third quarter ended September 30, 2014.
AAC: 36.61 (-0.72)

AAC Holdings, Inc. Announces Closing of Initial Public Offering
Business Wire - Tue Oct 07, 3:01PM CDT
AAC Holdings, Inc. (NYSE: AAC) (the "Company" , the parent holding company of American Addiction Centers, Inc., announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full of the underwriters' over-allotment option to purchase an additional 250,000 shares from the Company and 500,000 shares from certain selling stockholders. The Company estimates net proceeds from the offering to be approximately $69.1 million after deducting underwriting discounts and commissions and estimated offering expenses.
AAC: 36.61 (-0.72)

Online Retailer Wayfair Leads List Of 6 IPOs Thursday
at Investor's Business Daily - Thu Oct 02, 3:02PM CDT
Online retailer Wayfair popped 32% in its stock market debut Thursday, leading a list of six IPOs. Wayfair (W) raised $319 million by offering 11 million shares at 29, above its expected range of 25 to 28. The stock was above 38 in late-afternoon...
ATTO: 12.20 (+0.19), W: 23.50 (-0.17), FMSA: 6.56 (-0.04), VWR: 24.85 (-0.82), AAC: 36.61 (-0.72), CALA: 16.19 (+0.16), YDLE: 12.81 (-0.01), JPEP: 15.00 (+0.06)

AAC Holdings, Inc. Announces Pricing of Initial Public Offering
Business Wire - Wed Oct 01, 6:04PM CDT
AAC Holdings, Inc. (NYSE: AAC) (the "Company" , the parent holding company of American Addiction Centers, Inc., announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $15.00 per share, for a total of approximately $65.6 million of net proceeds after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with the offering, the Company and certain selling stockholders have granted the underwriters a 30-day over-allotment option to purchase up to an additional 750,000 shares of common stock. The shares are expected to begin trading tomorrow, October 2, 2014, on the New York Stock Exchange under the symbol "AAC." The offering is expected to close on October 7, 2014.
AAC: 36.61 (-0.72)

Solar Power, Biotechs Among 11 IPOs Planned This Week
at Investor's Business Daily - Mon Sep 29, 6:24PM CDT
The IPO market is maintaining a brisk pace with 11 scheduled this week, including a solar power company, three tech firms and three biotech companies. Vivint Solar (VSLR), a competitor to the Elon Musk-backed SolarCity (SCTY), plans to raise $350...
ATTO: 12.20 (+0.19), VWR: 24.85 (-0.82), JMEI: 14.14 (+0.84), ZEN: 24.63 (+0.21), VSLR: 8.17 (+0.09), JPEP: 15.00 (+0.06), W: 23.50 (-0.17), FMSA: 6.56 (-0.04), SCTY: 52.10 (-0.18), DERM: 17.90 (+0.99), AAC: 36.61 (-0.72), CALA: 16.19 (+0.16), AAVL: 36.75 (-0.21), YDLE: 12.81 (-0.01), JD: 28.00 (+0.70), BABA: 85.37 (-0.82)

Nasdaq stocks posting largest percentage increases
AP - Thu Feb 26, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AAOI: 11.82 (+1.31), SPNS: 7.83 (-0.02), FLML: 15.30 (+1.78), PCYC: 217.82 (-2.40), AKRX: 53.47 (+7.07), PGTI: 10.45 (+1.98), BNFT: 31.26 (-2.56), CBRX: 7.39 (+0.68), PLNR: 6.26 (+0.70), ONFC: 19.59 (+0.10), CYBX: 66.60 (+6.23)

Applied Optoelectronics' (AAOI) CEO Thompson Lin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 9:16PM CST

AAOI: 11.82 (+1.31)

Applied Optoelectronics posts 4Q profit
Automated Insights - Wed Feb 25, 5:24PM CST
SUGAR LAND, Texas (AP) _ Applied Optoelectronics Inc. (AAOI) on Wednesday reported fourth-quarter net income of $702,000, after reporting a loss in the same period a year earlier.
AAOI: 11.82 (+1.31)

Applied Optoelectronics beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 3:19PM CST

AAOI: 11.82 (+1.31)

Applied Optoelectronics to Announce Fourth Quarter and Year 2014 Financial Results on February 25, 2015
GlobeNewswire - Mon Jan 26, 3:03PM CST
Applied Optoelectronics, Inc. (Nasdaq:AAOI), a leading provider of fiber-optic access network products for the cable broadband, internet data center, and fiber-to-the-home markets, today announced that it will release financial results for its fourth quarter and year ended December 31, 2014 after U.S. markets close on Wednesday, February 25, 2015.
AAOI: 11.82 (+1.31)

Applied Optoelectronics Reports Preliminary Fourth Quarter 2014 Revenue
GlobeNewswire - Tue Jan 13, 3:03PM CST
Applied Optoelectronics, Inc. (Nasdaq:AAOI), a leading provider of fiber-optic access network products for the cable broadband, internet data center, and fiber-to-the-home markets, today announced preliminary revenue for the fourth quarter ended December 31, 2014.
AAOI: 11.82 (+1.31)

Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
ARCX: 18.77 (-0.71), AAOI: 11.82 (+1.31), BEAV: 63.42 (-0.30), BBRG: 13.32 (-0.36), BCOR: 14.67 (+0.40)

Applied Optoelectronics Completes Taiwan Factory Move
GlobeNewswire - Tue Dec 02, 7:30AM CST
Applied Optoelectronics, Inc. (Nasdaq:AAOI), a leading provider of fiber-optic access network products for the cable broadband, internet data center, and fiber-to-the-home markets, today announced the completion of the move to a new, larger factory in New Taipei City, Taiwan.
AAOI: 11.82 (+1.31)

Applied Optoelectronics, Inc. Ranked Number 374 Among the Fastest Growing Companies in North America on Deloitte's 2014 Technology Fast 500(TM)
GlobeNewswire - Thu Nov 13, 10:58AM CST
Applied Optoelectronics, Inc. (Nasdaq:AAOI) today announced it ranked No. 374 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. The ranking was based on Applied Optoelectronics' 214% revenue growth from 2009 to 2013.
AAOI: 11.82 (+1.31)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.31 (-0.08), HEAR: 2.48 (-0.09), JRJC: 5.94 (+0.09), CVO: 2.08 (-0.06), AAOI: 11.82 (+1.31), UNIS: 4.19 (+0.10), HIIQ: 7.09 (-0.04), CYAN: 8.12 (-0.04), PTX: 10.90 (+0.56), TRMR: 2.45 (+0.02), PRKR: 0.97 (-0.01), SUMR: 2.64 (-0.14), VSLR: 8.17 (+0.09), RVP: 4.21 (-0.01), ASCMA: 45.13 (+0.27), ICUI: 89.06 (+0.91), CALL: 7.54 (+0.05), DMD: 5.06 (+0.10), AST: 3.95 (+0.01), ASEI: 51.32 (-0.78)

Applied Optoelectronics (AAOI) Stock Lower After Earnings Miss
at The Street - Tue Nov 11, 9:55AM CST
Applied Optoelectronics (AAOI) is falling Tuesday after missing analysts' estimates for earnings in the third quarter
AAOI: 11.82 (+1.31)

Applied Optoelectronics misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:37PM CST

AAOI: 11.82 (+1.31)

Applied Optoelectronics Reports Sixth Consecutive Quarter of Record Revenue
GlobeNewswire - Mon Nov 10, 3:10PM CST
Third Quarter 2014 Highlights
AAOI: 11.82 (+1.31)

Infinera Stock Pops After Q3 Beat, Raised Outlook
at Investor's Business Daily - Thu Oct 23, 11:25AM CDT
Infinera stock soared to a more than six-year high Thursday after the fiber-optics parts maker posted Q3 earnings late Wednesday that blew past estimates and raised its Q4 guidance. Sunnyvale, Calif.-based Infinera (INFN) saw its stock rise 25% in...
FNSR: 21.07 (+0.28), AAOI: 11.82 (+1.31), JDSU: 13.32 (-0.07), CIEN: 20.91 (+0.12), INFN: 17.36 (+0.03)

iRobot Beats on Q3 Earnings, Hikes 2014 EPS Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 1:30PM CDT
iRobot Corporation (IRBT) reported strong earnings and improved year over year revenues for the third quarter of 2014.
AAOI: 11.82 (+1.31), AA: 15.11 (+0.11), IRBT: 33.05 (+0.66), AAPL: 130.41 (+1.62)

The Zacks Analyst Blog Highlights:iRobot, Alcoa, Applied Optoelectronics and Apple
PR Newswire - Wed Oct 22, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the iRobot Corporation (Nasdaq:IRBT-Free Report), Alcoa Inc. (NYSE:AA-Free Report), Applied Optoelectronics, Inc. (Nasdaq:AAOI-Free Report) and Apple Inc. (Nasdaq:AAPL-Free Report).
AAOI: 11.82 (+1.31), AA: 15.11 (+0.11)

iRobot to Ride Growth Trajectory on New Contracts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:52PM CDT
Premier robot manufacturing company iRobot Corporation (IRBT) announced the receipt of a new contract from the Naval Surface Warfare Center, Indian Head Explosive Ordnance Disposal Technology Division.
AAOI: 11.82 (+1.31), AA: 15.11 (+0.11), IRBT: 33.05 (+0.66), AAPL: 130.41 (+1.62)

Applied Optoelectronics, Inc. (AAOI) in Focus: Stock Soars 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:18AM CDT
Applied Optoelectronics, Inc. (AAOI) was a big mover last session, as the company saw its shares rise by above 10% on the day.
AMKR: 9.28 (+0.04), AMBA: 58.01 (+1.37), AAOI: 11.82 (+1.31), RMBS: 12.25 (+0.18)

Is AllianceBernstein Holding (AB) Stock A Great Combo of Value and Growth? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:47AM CST
AllianceBernstein Holding may be an interesting play thanks to its forward PE of 13.2, its P/S ratio of 0.91, and its decent dividend yield of 8.4%
AB: 28.38 (+0.92)

T. Rowe Price (TROW) Gains on Increasing Shareholder Value - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 20, 11:50AM CST
Shares of T. Rowe Price (TROW) gained nearly 2% at the end of the yesterday's trading session following the announcement of a special dividend along with a rise in regular quarterly cash dividend by this global investment management firm.
AB: 28.38 (+0.92), TROW: 83.32 (-0.20), JNS: 16.69 (+0.05), AMP: 135.34 (+0.02)

Top 3 Yielding Buy-Rated Stocks: PZN, AB, KCAP
at The Street - Thu Feb 19, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PZN: 8.30 (-0.06), AB: 28.38 (+0.92), KCAP: 7.44 (-0.05)

Ex-Dividends To Watch: 3 Stocks Going Ex-Dividend Tomorrow: FCO, AB, TRI
at The Street - Wed Feb 18, 9:00AM CST
FCO AB TRI are going ex-dividend tomorrow, Thursday, February 19, 2015
AB: 28.38 (+0.92), TRI: 39.59 (-0.24), FCO: 9.50 (+0.02)

AllianceBernstein Holding's (AB) CEO Peter Kraus on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 12:18PM CST

AB: 28.38 (+0.92)

More on AllianceBernstein results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:17AM CST

AB: 28.38 (+0.92)

AB Announces January 31, 2015 Assets Under Management
PR Newswire - Thu Feb 12, 6:06AM CST
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $476 billion during January 2015 from $474 billion at the end of December. The 0.4% increase was the result of total firmwide net inflows during the month, partially offset by market depreciation, including the negative impact of FX movements. By channel, net flows were positive in Institutions and Private Wealth Management and flat in Retail.
AB: 28.38 (+0.92)

AllianceBernstein beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 5:50AM CST

AB: 28.38 (+0.92)

AllianceBernstein Holding L.P. Announces Fourth Quarter Results
PR Newswire - Thu Feb 12, 5:46AM CST
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today reported financial and operating results for the fourth quarter ended December 31, 2014.
AB: 28.38 (+0.92)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST

NLSN: 45.79 (-0.69), RTIX: 5.20 (+0.06), AAP: 155.38 (-0.87), JAH: 53.50 (-0.29), LMNS: 11.18 (+0.01), THS: 85.21 (+0.35), RWLK: 16.83 (+0.48), CAB: 54.29 (+0.78), FAF: 35.33 (+0.15), HSP: 87.54 (+0.05), PNK: 25.99 (unch), MFA: 7.93 (-0.03), SPW: 88.91 (-0.76), MFC: 17.39 (-0.14), HIMX: 7.22 (-0.16), LNCE: 30.83 (+0.18), TIME: 24.04 (+0.01), AVP: 8.39 (-0.06), INCY: 87.54 (+1.89), NNN: 40.12 (-0.54), NWE: 54.03 (+0.06), COR: 46.89 (-0.68), MHFI: 103.49 (-0.19), NCI: 14.09 (+0.03), BWA: 61.55 (-0.24), HERO: 0.73 (-0.11), NRP: 8.00 (-0.15), STC: 37.14 (+0.34), AB: 28.38 (+0.92), CPLA: 65.69 (+0.22), TU: 35.59 (-0.03), IFF: 121.84 (-0.03), GNC: 48.18 (-0.26), MINI: 42.76 (+0.44), ACOR: 35.56 (-0.48), CVE: 17.38 (-0.49), SNI: 72.86 (-1.47), CCE: 46.16 (+0.31), K: 64.67 (-0.11), DPS: 78.19 (-0.84), BG: 81.31 (-0.74), AAWW: 45.51 (-0.51), Q: 64.95 (-0.08), SHPG: 247.84 (+2.74), MANU: 15.99 (-0.22), MPEL: 24.25 (-0.11), APA: 65.74 (-2.09), DBD: 35.55 (-0.39), MPW: 15.03 (-0.33), HE: 33.22 (-0.12), RYN: 27.10 (-0.08), CS: 24.59 (-0.60), PDS: 6.08 (-0.19), ANR: 1.30 (-0.07), SON: 47.19 (+0.20), SKYW: 15.00 (-0.06), LPNT: 72.10 (+1.14), RDN: 15.95 (+0.04), MDWD: 7.86 (+0.44), SCOR: 52.12 (+0.19), FLO: 21.43 (-0.11)

KKR Falls on Q4 Earnings Miss, Investment Income Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:24AM CST
KKR (KKR) reported adjusted economic net income per unit of 5 cents, substantially missing the Zacks Consensus Estimate of 40 cents. Moreover, the bottom line came in lower than the prior-year quarter figure of $1.04.
BAM: 54.77 (-0.43), AB: 28.38 (+0.92), FIG: 8.11 (+0.04), KKR: 23.49 (-0.07)

Jim Cramer's 'Mad Money' Recap: Stop Worrying About the Fed Rate Increase
at The Street - Mon Feb 09, 7:53PM CST
History tells us that growth and progress are positives for the stock market, Cramer says, and this time will be no different.
FTR: 8.00 (+0.05), NUE: 47.26 (-0.45), WFC: 55.15 (-0.18), BMY: 61.46 (+0.24), XLU: 45.28 (-0.30), AB: 28.38 (+0.92), VRSK: 72.26 (+0.08), RIG: 15.79 (-0.25), GILD: 104.19 (-0.24), MPC: 107.04 (+2.38), MRO: 28.00 (-1.06), TAL: 42.55 (+0.23), TWTR: 49.41 (+0.86), X: 24.23 (-0.68)

AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer
GlobeNewswire - Mon Feb 02, 11:26AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.
AB: 28.38 (+0.92)

AB to Report Fourth Quarter 2014 Results on Thursday, February 12, 2015
PR Newswire - Thu Jan 29, 12:15PM CST
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that Fourth Quarter 2014 financial and operating results will be released on Thursday, February 12, 2015. Management will conduct a teleconference call beginning at 8:00 am (ET), following the release of its financial results. The call will be hosted by Peter S. Kraus, Chairman and Chief Executive Officer, and John C. Weisenseel, Chief Financial Officer.
AB: 28.38 (+0.92)

AllianceBernstein Launches New Branding Initiative
PR Newswire - Tue Jan 20, 6:50AM CST
AllianceBernstein L.P. ("AllianceBernstein" , a global investment management firm with US $474 billion in assets under management, today announced changes to its brand identity and messaging to better reflect the evolution of the firm. Over the past few years, the company has expanded across asset classes and markets, finding dynamic new ways to solve investors' challenges. Today, the firm is able to move its clients' vision forward like never before by offering a unique combination of industry-leading talent, an integrated global structure, a culture of collaboration, intense client focus and the ability to deliver differentiated results. This new brand initiative, Ahead of Tomorrow, captures both the company's progress and its unique approach to innovating and delivering for clients. The new brand name, "AB," and logo better embody the firm's distinct offerings and unified culture.
AB: 28.38 (+0.92)

AllianceBernstein AUM fall in December
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:04AM CST

AB: 28.38 (+0.92)

AllianceBernstein Announces December 31, 2014 Assets Under Management
PR Newswire - Wed Jan 14, 7:54AM CST
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that preliminary assets under management decreased to $474 billion during December 2014 from $481 billion at the end of November. The 1.5% decrease was due to market depreciation and net outflows during the month across all three distribution channels.
AB: 28.38 (+0.92)

AB Science: The Data and Safety Monitoring Board Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis
GlobeNewswire - Tue Jan 13, 10:48AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 28.38 (+0.92)

3 Buy-Rated Dividend Stocks: DMLP, MAIN, AB
at The Street - Thu Jan 08, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
DMLP: 23.94 (-0.38), AB: 28.38 (+0.92), MAIN: 30.69 (-0.24)

AllianceBernstein Launches Multi-Manager Target-Date Series Co-managed with Morningstar Associates
PR Newswire - Wed Jan 07, 9:36AM CST
AllianceBernstein L.P. (AllianceBernstein), a global investment management firm with $481 billion in assets under management, today announced that its multi-manager target-date series, AB Multi-Manager Select Retirement Funds, co-managed with Morningstar Associates, LLC, a registered investment advisor and wholly owned subsidiary of Morningstar, Inc., is now available to investors.
AB: 28.38 (+0.92), MORN: 74.93 (-0.34)

Community Bank System Worth Keeping On The Radar
Stephen Rosenman - at Seeking Alpha - Wed Feb 25, 9:00AM CST

EWBC: 40.42 (+0.10), ABCB: 26.29 (+0.09), CBU: 35.51 (+0.27)

How it All Plays Out: Complementary Reports on American National, ANICO, American River Bankshares, Ameris, and AMERISAFE
PR Newswire - Thu Feb 05, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including American National (NASDAQ: AMNB), ANICO (NASDAQ: ANAT), American River Bankshares, (NASDAQ: AMRB), Ameris (NASDAQ: ABCB), and AMERISAFE (NASDAQ: AMSF). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AMRB: 9.57 (-0.02), AMSF: 43.17 (+0.13), AMNB: 22.35 (-0.02), ANAT: 105.85 (+1.09), ABCB: 26.29 (+0.09)

Ameris Bancorp's (ABCB) CEO Edwin Hortman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 3:20PM CST

ABCB: 26.29 (+0.09)

More cost cuts at Bank of America
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 12:16PM CST

ABCB: 26.29 (+0.09), BAC: 16.04 (-0.45)

Ameris Bancorp misses Street 4Q forecasts
Automated Insights - Thu Jan 29, 8:15AM CST
MOULTRIE, Ga. (AP) _ Ameris Bancorp (ABCB) on Thursday reported fourth-quarter net income of $10.6 million.
ABCB: 26.29 (+0.09)

Ameris Bancorp misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 7:49AM CST

ABCB: 26.29 (+0.09)

Ameris Bancorp Announces Private Placement Of Common Stock
PR Newswire - Thu Jan 29, 7:32AM CST
AMERIS BANCORP (NASDAQ-GS: ABCB), Ameris Bancorp ("Ameris" or the "Company" today announced the sale of shares of the Company's common stock at a price of $22.50 per share to institutional accredited investors through a private placement. The Company has received commitments for the sale of up to 5,320,000 shares and is in the process of closing the issuance, which is expected to be completed by January 30, 2015. The Company expects to receive net proceeds from the private placement of approximately $114.5 million, which it intends to use, in part, to fund the cash consideration for its recently announced acquisitions of Merchants & Southern Banks of Florida, Inc. and eighteen Bank of America branches located in North Florida and South Georgia.
ABCB: 26.29 (+0.09)

Ameris Bancorp Announces Record Earnings For 2014 And Two Strategic Acquisitions
PR Newswire - Thu Jan 29, 7:30AM CST
AMERIS BANCORP (NASDAQ-GS: ABCB), Ameris Bancorp ("Ameris" or the "Company" today announced earnings and operating results for the quarter and twelve months ended December 31, 2014, and simultaneously announced the signing of definitive agreements to purchase Merchants & Southern Banks of Florida, Inc. and eighteen Bank of America branches.
ABCB: 26.29 (+0.09)

Ameris Bancorp To Announce Results For 2014
PR Newswire - Wed Jan 28, 3:01PM CST
AMERIS BANCORP (NASDAQ-GS: ABCB), Ameris Bancorp ("Ameris" or the "Company" today announced that it intends to release the results of its operations for 2014 before the market opens on Thursday, January 29, 2015. Edwin W. Hortman, Jr., President and Chief Executive Officer, and Dennis J. Zember Jr., Executive Vice President and Chief Financial Officer, will host a teleconference at 11:00 a.m. EDT on that day to discuss the Company's results and answer appropriate questions.
ABCB: 26.29 (+0.09)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST

AGTC: 21.69 (+0.34), BXE: 2.85 (-0.06), ROKA: 4.00 (-0.02), ALNY: 104.39 (-2.27), NCT: 4.69 (-0.01), SSRI: 5.30 (-0.07), ABCB: 26.29 (+0.09), OSIR: 17.34 (-0.14), XCO: 2.10 (-0.15), JDST: 9.08 (-0.21)

Has Ameris Bancorp Topped Out?
Profit Fan - at Seeking Alpha - Fri Oct 31, 1:49PM CDT

ABCB: 26.29 (+0.09)

Ameris Bancorp EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 7:46AM CDT

ABCB: 26.29 (+0.09)

Ameris Bancorp Reports Operating Net Income Of $12.0 Million, Or $0.44 Per Diluted Share, For Third Quarter 2014
PR Newswire - Wed Oct 22, 7:30AM CDT
AMERIS BANCORP (NASDAQ-GS: ABCB), today reported operating net income of $12.0 million, or $0.44 per diluted share, for the quarter ended September 30, 2014, compared to $6.6 million, or $0.27 per diluted share, for the quarter ended September 30, 2013. For the year to date period ending September 30, 2014, the Company reported operating net income of $30.5 million, or $1.17 per diluted share, compared to $17.3 million, or $0.71 per diluted share, for the same period in 2013. During the third quarter of 2014, the Company completed the conversion of Coastal Bankshares, Inc. ("Coastal" and recorded additional merger expenses totaling approximately $383,000, or $0.01 per share, on an after-tax basis. Including these charges, the Company reported net income for the third quarter of 2014 of $11.7 million, or $0.43 per share. Commenting on the Company's quarterly results, Edwin W. Hortman, Jr., the Company's President and Chief Executive Officer, said, "Our bankers turned in an outstanding quarter resulting in an 87% improvement in net earnings available to common shareholders compared to the same quarter in 2013. Additionally, our system conversion of Coastal was successful and we are working diligently to ensure that the cost savings we identified are realized and in place during the fourth quarter of 2014."
ABCB: 26.29 (+0.09)

As Market Slides, Several Growth Names Hang In There
at Investor's Business Daily - Thu Oct 16, 5:58PM CDT
A weak market has resulted in plenty of damage to leading growth stocks, but several institutional-quality names -- and some lesser-known ones -- have weathered the market storm quite well. Keurig Green Mountain (GMCR) is trading tightly near highs...
GMCR: 124.89 (+0.79), HDB: 61.18 (+0.82), TYL: 119.97 (+0.57), ABCB: 26.29 (+0.09), DPZ: 104.00 (+0.07), INFY: 36.58 (-0.19), MFRM: 60.89 (+0.32), ROST: 99.05 (+0.59)

Ameris Bancorp Up 10.8% Since SmarTrend Uptrend Call (ABCB)
Comtex SmarTrend(R) - Tue Aug 26, 9:26AM CDT
SmarTrend identified an Uptrend for Ameris Bancorp (NASDAQ:ABCB) on June 6th, 2014 at $21.67. In approximately 3 months, Ameris Bancorp has returned 10.78% as of today's recent price of $24.00.
ABCB: 26.29 (+0.09)

Ameris Bancorp Reports Operating Net Income Of $10.0 Million, Or $0.40 Per Diluted Share, For Second Quarter 2014
PR Newswire - Tue Jul 22, 3:01PM CDT
AMERIS BANCORP (NASDAQ-GS: ABCB), Moultrie, Georgia, today reported operating net income of $10.0 million, or $0.40 per diluted share, for the quarter ended June 30, 2014, compared to $6.2 million, or $0.26 per diluted share, for the quarter ended June 30, 2013. For the year to date period ending June 30, 2014, the Company reported operating net income of $18.1 million, or $0.71 per diluted share, compared to $11.1 million, or $0.46 per diluted share, for the same period in 2013. During the second quarter of 2014, the Company completed the acquisition of Coastal Bankshares, Inc. ("Coastal" and recorded approximately $1.90 million, or $0.075 per share, of after-tax merger related charges. Including these charges, the Company reported net income in the second quarter of 2014 of $8.1 million, or $0.32 per common share. Commenting on the Company's quarterly results, Edwin W. Hortman, Jr., the Company's President and Chief Executive Officer, said, "I am pleased with our operating results for the second quarter of 2014. Our operating return on average assets and return on tangible equity for the quarter improved from the prior period to 1.15% and 15.85%, respectively. Strong trends in loan growth, funded mostly with non-rate sensitive deposits, very solid mortgage results and over $1.1 million of SBA revenue were among the factors contributing to a successful quarter."
ABCB: 26.29 (+0.09)

Anchor BanCorp Wisconsin EPS of $0.55
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 5:27AM CST

ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin Inc. Announces Fourth Quarter and Year End Results
GlobeNewswire - Fri Feb 06, 5:30PM CST
Anchor BanCorp Wisconsin Inc. (the "Company" (Nasdaq:ABCW) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014. Anchor concluded a strong, profitable year with net income of $14.6 million or $1.60 per diluted common share.
ABCW: 34.07 (+0.12)

Quarterly Report Card: Special Research on Ames National, Anchor Bancorp,Anchor BanCorp Wisconsin, Arrow, and ASB Bancorp
PR Newswire - Thu Feb 05, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ames National (NASDAQ: ATLO), Anchor Bancorp (NASDAQ: ANCB), Anchor BanCorp Wisconsin (NASDAQ: ABCW), Arrow (NASDAQ: AROW), and ASB Bancorp (NASDAQ: ASBB). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AROW: 27.07 (+0.21), ATLO: 25.00 (+0.21), ASBB: 20.58 (+0.55), ABCW: 34.07 (+0.12), ANCB: 22.08 (+0.12)

Anchor BanCorp Wisconsin Inc. Announces Definitive Agreement to Sell Viroqua Branch
GlobeNewswire - Tue Jan 27, 5:35PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Viroqua branch to Royal Bank of Elroy, Wisconsin. The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of May 2015. Financial terms of the transaction were not disclosed.
ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin Inc. Finalizes Sale of Richland Center Branch to The Peoples Community Bank
GlobeNewswire - Wed Dec 31, 3:56PM CST
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has finalized the sale of its Richland Center branch to The Peoples Community Bank (Peoples) as previously announced. The transaction closed today following receipt of the necessary regulatory approvals and satisfaction of customary closing conditions. Financial terms of the transaction were not disclosed.
ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin Inc. to Join Multiple Russell Indexes
GlobeNewswire - Fri Dec 19, 3:30PM CST
Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW) today announced that it was included on the preliminary list of quarterly initial public offering additions to the broad-market Russell Global(R), Russell 3000(R), Russell 2000(R) and Russell Microcap(R) Indexes to be effective at the close of the U.S. market on Friday, December 19, 2014, according to a preliminary list of additions posted December 15, 2014 on www.russell.com/indexes.
ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin reports Q3 profit
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:52PM CST

ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin Inc. Announces Third Quarter Results
GlobeNewswire - Tue Nov 04, 4:07PM CST
Anchor BanCorp Wisconsin Inc. (the "Company" (Nasdaq:ABCW), today announced its financial results for the quarter ended September 30, 2014. Net income was $5.0 million for the quarter compared to $2.6 million in the quarter ended June 30, 2014 and compared to net income of $113.3 million for the quarter ended September 30, 2013. Earnings per share were $0.55 for the quarter compared to $0.29 for the quarter ended June 30, 2014, and $5.47 per share for the quarter ended September 30, 2013. Income per share available to common equity was $10.24 for the quarter ended September 30, 2013. The prior year quarter income includes non-recurring extinguishment of debt income of $134.5 million which occurred as part of the recapitalization transaction we completed in September, 2013.
ABCW: 34.07 (+0.12)

Anchor Bancorp Wisconsin Inc. Announces Definitive Agreement to Sell Richland Center Branch
GlobeNewswire - Thu Oct 30, 5:30PM CDT
AnchorBank, fsb, a wholly owned subsidiary of Anchor BanCorp Wisconsin Inc. (Nasdaq:ABCW), today announced that it has entered into a definitive agreement for the sale of its Richland Center retail banking branch to The Peoples Community Bank (Peoples). The transaction is subject to regulatory approval and customary closing conditions and is targeted for closing by the end of December 2014. Financial terms of the transaction were not disclosed.
ABCW: 34.07 (+0.12)

U.S. IPO Weekly Recap: With Just 3 IPOs, More Companies Postpone Than Go Public
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 26, 12:22PM CDT
Three IPOs raised $164 million, bringing the year's total up to 231 offerings and $74 billion in proceeds. Six deals were expected to raise $550 million to make it the first week in over a month to raise under $1 billion. However, three of those...
ABCW: 34.07 (+0.12), PRTO: 10.65 (+0.02)

Nice start for Anchor BanCorp after IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:52AM CDT

ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin prices IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 6:52AM CDT

ABCW: 34.07 (+0.12)

Anchor BanCorp Wisconsin Inc. Announces Pricing of Initial Public Offering of Common Stock
GlobeNewswire - Tue Oct 21, 6:27PM CDT
Anchor BanCorp Wisconsin Inc. (the "Company" , the parent holding company of AnchorBank, fsb, today announced the pricing of its initial public offering of 371,959 shares of its common stock at a price to the public of $26.00 per share. The Company is offering 250,000 shares of common stock and selling stockholders are offering 121,959 shares of common stock. In addition, the Company has granted the underwriters an option to purchase up to an additional 55,794 shares of common stock from the Company to cover over-allotments. The shares are expected to begin trading on October 22, 2014 on the NASDAQ Global Select Market under the symbol "ABCW." The offering is expected to close on October 27, 2014, subject to the satisfaction of customary closing conditions.
ABCW: 34.07 (+0.12)

Week Ahead: 5 IPOs Planned For The Week Of October 20 Include E-Cigarettes And Asset Management
Renaissance Capital IPO Research - Seeking Alpha - Mon Oct 20, 7:46AM CDT
5 IPOs are expected to raise $456 million during the week of October 20. After five straight weeks of raising over $1 billion, the IPO market appears to have chilled due to the broader market sell-off and weaker returns. Aside from two small...
STIM: (), VBAY: (), NSIG: (), ABCW: 34.07 (+0.12), VKTX: ()

Cyberonics Soars On Earnings Beat, Tax Inversion Deal
at Investor's Business Daily - Thu Feb 26, 12:58PM CST
Shares of Cyberonics (CYBX) gapped up to a record high Thursday after the company reported better than expected earnings growth and said it is merging with Italy's Sorin and moving its headquarters to Europe despite new Treasury rules intended to...
ABMD: 61.00 (+0.83), QSR: 43.48 (+0.79), MDT: 78.81 (+0.18), BAX: 68.67 (-0.19), SHPG: 247.84 (+2.74), EW: 134.90 (+0.85), ABBV: 60.52 (-0.10), CYBX: 66.60 (+6.23)

DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 8:54AM CST
DexCom Inc (DXCM) reported fourth-quarter 2014 EPS of 2 cents per share, which compares favorably with the Zacks Consensus Estimate of a loss of 3 cents and year-ago loss of 4 cents per share.
ABMD: 61.00 (+0.83), DXCM: 61.96 (-1.38), LMNX: 15.97 (-0.24), AAPL: 130.41 (+1.62)

Greatbatch Q4 Earnings Top on Solid Margins, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 8:08AM CST
Greatbatch Inc. (GB) reported adjusted EPS of 65 cents in the fourth quarter of 2014, which beat the Zacks Consensus Estimate by 6 cents.
ABMD: 61.00 (+0.83), GB: 54.22 (+0.08), INGN: 33.83 (-0.12), LMNX: 15.97 (-0.24)

HeartWare Recalls Old Ventricular Assist System Controllers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 6:00PM CST
HeartWare International, Inc. (HTWR) is issuing a voluntary Urgent Medical Device Recall for its older HeartWare Ventricular Assist System Controllers, in the U.S.
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), LMNX: 15.97 (-0.24), HTWR: 86.38 (-3.91)

Adeptus Health Q4 Earnings Miss, Revenues in Line; Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 9:20AM CST
Operator of freestanding emergency rooms in the U.S., Adeptus Health Inc. (ADPT) announced fourth-quarter 2014 adjusted earnings per share (EPS) of 8 cents, which missed the Zacks Consensus Estimate by a couple of cents.
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), LMNX: 15.97 (-0.24), ADPT: 44.60 (+1.85)

Teleflex Hits 52-Week High on Strong Q4, Strategic Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:16AM CST
Shares of Teleflex Inc (TFX) scaled a new 52-week high of $123.09 in mid-day trading on Feb 23.
ABMD: 61.00 (+0.83), FLDM: 42.44 (+0.76), TFX: 121.22 (+0.22), LMNX: 15.97 (-0.24)

Teleflex (TFX) Q4 Earnings, Revenues Top Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 9:30AM CST
Teleflex Inc. (TFX) reported fourth-quarter 2014 adjusted earnings of $1.43 per share (EPS) which handily beat the Zacks Consensus Estimate of $1.39
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), TFX: 121.22 (+0.22), LMNX: 15.97 (-0.24)

Accuray (ARAY) Catches Eye: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 8:46AM CST
Accuray Incorporated (ARAY) was a big mover last session, as the company saw its shares rise over 5% on the day.
ABMD: 61.00 (+0.83), ARAY: 8.71 (+0.18)

Insider Trading Alert - ABMD, CCMP And SGMO Traded By Insiders
at The Street - Thu Feb 19, 10:15AM CST
Stocks with insider trader activity include ABMD, CCMP and SGMO
ABMD: 61.00 (+0.83), SGMO: 16.97 (+0.11), CCMP: 52.05 (+0.38)

Exactech (EXAC) Q4 Earnings Top, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 8:56AM CST
Producer of bone and joint restoration products, Exactech Inc. (EXAC), announced adjusted earnings per share (EPS) of 36 cents in the fourth quarter of 2014, which beat the Zacks Consensus Estimate by a couple of cents.
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), EXAC: 22.73 (-0.17), LMNX: 15.97 (-0.24)

Patterson Companies (PDCO) Lags Q3 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 8:38AM CST
Patterson Companies Inc. (PDCO) reported third-quarter fiscal 2015 adjusted earnings of 55 cents per share, which missed the Zacks Consensus Estimate of 59 cents and also declined 3.5% from the year-ago quarter.
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), PDCO: 49.44 (+0.11), LMNX: 15.97 (-0.24)

Edwards Lifesciences (EW) Shines on Solid Q4, THV Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 7:31AM CST
Edwards Lifesciences (EW) reported adjusted earnings per share of $1.06 in the quarter, exceeding the Zacks Consensus Estimate by a solid 12.8%.
ABMD: 61.00 (+0.83), EW: 134.90 (+0.85), LMNX: 15.97 (-0.24), HOLX: 32.21 (+0.15)

Masimo (MASI) Q4 Earnings, Revenues Top Estimates; Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:06AM CST
Masimo Corp (MASI) reported adjusted earnings per share (EPS) of 40 cents in the fourth quarter of 2014 (ending Jan 3, 2015), handily beating the Zacks Consensus estimate of 37 cents.
ABMD: 61.00 (+0.83), MASI: 29.90 (-0.15), INGN: 33.83 (-0.12), LMNX: 15.97 (-0.24)

CryoLife (CRY) Down as Q4 Earnings Fall; Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:03AM CST
CryoLife Inc. (CRY) reported adjusted earnings per share (EPS) of 4 cents in the fourth quarter of 2014, lower than the year-ago equivalent of 7 cents.
ABMD: 61.00 (+0.83), BCR: 170.94 (-0.68), LMNX: 15.97 (-0.24), CRY: 10.72 (+0.08)

Abiomed Hits 52-Week High on Solid Q3, Impella RP Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 9:26AM CST
The bullish run reflects Abiomed Inc.'s (ABMD) strong third-quarter fiscal 2015 results, a raised fiscal 2015 guidance and the recent FDA HDE approval for its Impella RP System.
ABMD: 61.00 (+0.83), FLDM: 42.44 (+0.76), EW: 134.90 (+0.85), LMNX: 15.97 (-0.24)

Lumenis Ltd. (LMNS) in Focus: Stock Jumps 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 8:21AM CST
Lumenis Ltd. (LMNS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
ABMD: 61.00 (+0.83), LMNS: 11.18 (+0.01)

Cepheid's TB Test Wins FDA Clearance for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 1:00PM CST
Cepheid's (CPHD) Xpert MTB/RIF was shipped to over 10% of the company's North American installed base in its debutant quarter of launch.
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), CPHD: 58.44 (+0.53), LMNX: 15.97 (-0.24)

Varian Medical's ProBeam Proton Therapy Now in Denmark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:43PM CST
In addition to the ProBeam system, Varian Medical Systems Inc. (VAR) will provide the Denmark center with its ARIA information management software.
ABMD: 61.00 (+0.83), VAR: 92.45 (-1.16), INGN: 33.83 (-0.12), LMNX: 15.97 (-0.24)

Allscripts Sunrise EHR: IHMC's Choice for Flagship Hospital - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 1:57PM CST
Allscripts recently announced that its Sunrise Acute Care has been selected by Texas-based International Hospital Management Corp. (IHMC).
ABMD: 61.00 (+0.83), INGN: 33.83 (-0.12), MDRX: 12.75 (-0.02), SURG: 4.42 (-0.05)

Bioanalytical Systems' Breakeven Q1 Earnings, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:00AM CST
Bioanalytical Systems (BASI) reported adjusted breakeven earnings per share (EPS) in the first quarter of fiscal 2015, which was lower by 3 cents on a year-over-year basis
ABMD: 61.00 (+0.83), BASI: 1.99 (-0.06), INGN: 33.83 (-0.12), SURG: 4.42 (-0.05)

Short Interest Decreases By 11.6% For ACLS
MarketNewsVideo.com - Thu Feb 26, 2:21PM CST
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 276,768 share decrease in total short interest for Axcelis Technologies Inc , to 2,115,890, a decrease of 11.57% since 01/30/2015. ...
ACLS: 2.86 (+0.03)

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
CHGG: 7.99 (-0.39), AYR: 22.94 (-0.28), CASY: 89.49 (+0.41), ACLS: 2.86 (+0.03), CHFC: 30.54 (+0.22)

Is Axcelis Technologies (ACLS) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 7:34AM CST
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Axcelis Technologies.
ACLS: 2.86 (+0.03)

Can Axcelis Technologies (ACSL) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 7:52AM CST
Axcelis Technologies firm in the Electronic Manufacturing Machinery space is seeing solid activity on the earnings estimate revision front
ACLS: 2.86 (+0.03)

How Axcelis Technologies (ACLS) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:46AM CST
Axcelis Technologies is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
ACLS: 2.86 (+0.03)

Axcelis Sends Letter To Stockholders Outlining Actions Taken To Create Stockholder Value
PR Newswire - Fri Feb 13, 7:30AM CST
Axcelis Technologies, Inc. (Nasdaq: ACLS) today released the following letter to the Company's stockholders outlining the significant actions the Company's Board of Directors and management team have taken to create stockholder value and best position the Company for the future.
ACLS: 2.86 (+0.03)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
AUO: 5.26 (-0.08), AMKR: 9.28 (+0.04), ABG: 79.02 (+1.06), ALE: 54.73 (-0.22), ACLS: 2.86 (+0.03)

Axcelis rallies after Q4 beat, strong Q1 guidance
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 4:09PM CST

ACLS: 2.86 (+0.03)

Why Shares of Axcelis Technologies Inc. Surged Today
Timothy Green, The Motley Fool - Motley Fool - Fri Feb 06, 2:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Axcelis Technologies , a provider of...
ACLS: 2.86 (+0.03)

Axcelis Technologies' (ACLS) CEO Mary Puma on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 10:35PM CST

ACLS: 2.86 (+0.03)

Axcelis beats Street 4Q forecasts
Automated Insights - Thu Feb 05, 6:01PM CST
BEVERLY, Mass. (AP) _ Axcelis Technologies Inc. (ACLS) on Thursday reported fourth-quarter profit of $165,000.
ACLS: 2.86 (+0.03)

Axcelis Technologies (ACLS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 05, 3:55PM CST

ACLS: 2.86 (+0.03)

Axcelis Technologies beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 3:12PM CST

ACLS: 2.86 (+0.03)

Axcelis Announces Financial Results For Fourth Quarter And Full Year 2014
PR Newswire - Thu Feb 05, 3:01PM CST
Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the fourth quarter and full year ended December 31, 2014. Recent highlights include:
ACLS: 2.86 (+0.03)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:35PM CST

BEBE: 3.63 (+0.01), ACET: 21.35 (+0.05), ARCW: 6.29 (+0.05), CPST: 0.71 (+0.01), AIV: 37.10 (-0.37), DV: 36.65 (-0.32), EGAN: 3.69 (+0.01), CUTR: 12.76 (-0.07), MTD: 314.66 (-2.26), PXLW: 5.16 (-0.06), LNKD: 270.76 (+1.76), ADNC: 4.62 (-0.01), LGF: 32.94 (-0.03), AHL: 45.87 (+0.16), HME: 66.37 (-1.11), PDFS: 18.77 (+0.58), MCK: 229.46 (-0.14), KRG: 28.13 (-0.15), ATHN: 131.29 (+0.71), PCTY: 29.70 (-0.20), BRS: 61.36 (-0.44), ECOM: 10.09 (+0.40), FWM: 5.68 (-0.01), EXPE: 93.25 (-1.36), NTGR: 32.25 (+0.18), IMPV: 46.38 (-0.46), OLN: 28.34 (-0.36), MRIN: 6.60 (+0.06), BWLD: 191.74 (-0.71), ASYS: 10.81 (-0.13), DCT: 35.79 (-0.14), BCOV: 7.83 (-0.23), MXWL: 7.26 (+0.05), CME: 96.02 (-0.51), ATVI: 23.35 (-0.10), KIM: 26.17 (-0.28), P: 15.18 (-0.25), BMI: 58.31 (-0.59), OUTR: 63.65 (-1.60), CTRL: 12.95 (+0.20), GPRO: 44.66 (-0.39), ECHO: 29.36 (+0.36), RDEN: 16.60 (+0.16), NUAN: 14.37 (+0.22), ATR: 66.26 (+0.41), ACLS: 2.86 (+0.03), EGOV: 17.91 (+0.45), PDM: 18.19 (-0.25), FLDM: 42.44 (+0.76), BRKS: 12.02 (+0.07), FLT: 155.41 (-1.53), ASEI: 51.32 (-0.78), ENH: 63.03 (-0.24), CALD: 14.52 (unch), ONNN: 12.86 (+0.84), LF: 2.56 (-0.05)

Axcelis Announces Closure Of Sale Leaseback Transaction
PR Newswire - Mon Feb 02, 3:01PM CST
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that on January 30, 2015, it sold the Company's headquarter building at 108 Cherry Hill Drive, located on approximately 37 acres in Beverly, Massachusetts to Beverly Property Owner LLC, an affiliate of Middleton Partners, based in Northbrook, Illinois, for the purchase price of $49 million. Axcelis has entered into a 22 year lease of the property and will retain ownership of approximately 23 acres of adjacent property.
ACLS: 2.86 (+0.03)

Fujifilm Posts Improved Y/Y Q3 Results, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 2:30PM CST
In third-quarter fiscal 2015 (ended Dec 31, 2014) Fujifilm Holdings Corporation (FUJIY) reported a net income of ??53.3 billion ($465.9 million), up 71.8% year over year.
ACPW: 2.00 (unch), ACLS: 2.86 (+0.03), AAPL: 130.41 (+1.62)

4 Stocks Under $10 Making Big Moves: Aegon, Care.com and More
at The Street - Thu Jan 29, 12:20PM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
AMSC: 0.86 (unch), CRCM: 8.00 (-0.04), ACLS: 2.86 (+0.03), AEG: 7.75 (-0.10)

Axcelis Receives Multiple Orders From Several Foundries For Purion XE High Energy Implanter
PR Newswire - Thu Jan 29, 7:00AM CST
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced that it has received multiple orders for its innovative Purion XE(TM) high energy implanter. The orders include the penetration of two new 200mm foundries and a follow on order from a 300mm foundry. The Purion XE's will be used in high volume production of 28nm specialty logic, MEMS, image sensor and power devices. The systems are expected to ship in the first quarter.
ACLS: 2.86 (+0.03)

Corning Reports Strong 4Q Earnings, Positive for 2015 - Analyst Blog
Sejuti Banerjea - Zacks Investment Research - Wed Jan 28, 8:16AM CST
Corning (GLW) has reported fourth-quarter core earnings of 45 cents, ahead of the Zacks Consensus Estimate of 38 cents.
ADI: 58.88 (-0.11), GLW: 24.47 (-0.13), ACLS: 2.86 (+0.03), ADBE: 78.96 (+0.89)

AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 04, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows:
ACRX: 8.96 (+0.19)

Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 17.1% Annualized Using Options
StockOptionsChannel.com - Mon Jan 26, 10:40AM CST
Investors considering a purchase of AcelRx Pharmaceuticals Inc shares, but tentative about paying the going market price of $6.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
ACRX: 8.96 (+0.19)

Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?
at The Street - Thu Jan 15, 8:59AM CST
AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?
ACRX: 8.96 (+0.19)

AcelRx (ACRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:46AM CST
AcelRx (ACRX) Shares March Higher, Can It Continue?
ACRX: 8.96 (+0.19)

5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More
at The Street - Fri Jan 09, 9:32AM CST
These setups often produce monster moves higher in very short time frames.
ACRX: 8.96 (+0.19), NOG: 8.16 (-0.32), CPE: 7.40 (+0.01), PHMD: 1.85 (+0.07), NKA: 1.79 (-0.11)

Minerva Neurosciences (NERV) in Focus: Stock Jumps 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 8:21AM CST
Minerva Neurosciences, Inc. (NERV) was a big mover last session, as the company saw its shares rise over 8% on the day.
ACRX: 8.96 (+0.19), NERV: 5.09 (-0.07)

Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:44AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares gain over 7%
ACRX: 8.96 (+0.19), CEMP: 32.05 (+1.64)

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BAM: 54.77 (-0.43), AGN: 232.40 (-0.08), ACRX: 8.96 (+0.19), COLB: 28.32 (+0.26), CALD: 14.52 (unch)

A Little Impatience And A Lot Of Skepticism Provides An Excellent Risk-Reward In AcelRx Pharmaceuticals
Buddy Lyons - at Seeking Alpha - Thu Jan 01, 5:00AM CST

ACRX: 8.96 (+0.19)

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BIRT: 6.60 (+0.01), ACRX: 8.96 (+0.19), AWR: 39.84 (-0.36), ABBV: 60.52 (-0.10), ALGT: 184.55 (+3.08)

AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell
at The Street - Tue Dec 30, 9:00AM CST
AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
ACRX: 8.96 (+0.19)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BIRT: 6.60 (+0.01), ACRX: 8.96 (+0.19), AWR: 39.84 (-0.36), ACPW: 2.00 (unch), ADUS: 21.58 (+0.19)

Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 8.96 (+0.19), XNCR: 15.27 (+0.17)

Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.71 (+0.80), ACRX: 8.96 (+0.19), EGLT: 14.98 (+0.70), AMGN: 158.97 (+0.89), NKTR: 12.98 (-0.24)

Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 8.96 (+0.19), LCI: 65.17 (+0.95), INFI: 16.04 (+0.92), IG: 11.20 (+0.18)

La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 8.96 (+0.19), LCI: 65.17 (+0.95), LJPC: 20.25 (+0.06), IG: 11.20 (+0.18)

Sedation - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxkbln/sedation) has announced the addition of the "Sedation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - AcelRx Pharmaceuticals - Paion - Maruishi Pharmaceutical - NanoMedex Pharmaceuticals - Advicenne Pharma For more information visit http://www.researchandmarkets.com/research/fxkbln/sedation
ACRX: 8.96 (+0.19)

Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:31AM CST
AcelRx Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ACRX: 8.96 (+0.19)